World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT01329731
Date of registration: 01/04/2011
Prospective Registration: No
Primary sponsor: Gaba International AG
Public title: Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients
Scientific title: White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months
Date of first enrolment: March 2011
Target sample size: 48
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT01329731
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment  
Phase:  Phase 4
Countries of recruitment
Germany
Contacts
Key inclusion & exclusion criteria

Inclusion Criteria:

- Written informed consent

- Healthy volunteers (=11 years) scheduled for bracket removal

- = 1 WSL with a modified score 1 or 2 (Gorelick et al. 1982) on UFT at debonding

Exclusion Criteria:

- Known hypersensitivity or allergy to study products and standard toothpaste
ingredients and/or dental material used in the present study

- Known hypersensitivity or allergy to placebo gel ingredients

- Alterations in the teeth's enamel, e.g. hypoplasia, fluorosis

- Any illness/condition potentially affecting the study outcome at investigator's
discretion

- Known pregnancy or breast feeding during the course of the study



Age minimum: 11 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Tooth; Lesion, White Spot Lesions
Intervention(s)
Drug: negative control (placebo)
Drug: elmex® gelée
Primary Outcome(s)
WSL-size change [Time Frame: 12 weeks]
Secondary Outcome(s)
Caries activity [Time Frame: Baseline up to 24 weeks]
WSL index on all upper front teeth [Time Frame: Baseline up to 24 weeks]
DMFT index: Dental health of all teeth [Time Frame: Baseline, 24 weeks]
WSL-size change [Time Frame: Baseline up to 24 weeks]
Gingival bleeding index on all upper front teeth [Time Frame: Baseline up to 24 weeks]
Plaque index (Silness and Löe 1964)on all upper front teeth [Time Frame: Baseline up to 24 weeks]
WSL-brightness change [Time Frame: Baseline up to 24 weeks]
Secondary ID(s)
2010-020538-24
GASAS-1002X
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
PD Dr. Christian Heumann
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history